371 related articles for article (PubMed ID: 30135448)
1. Genomic patterns of progression in smoldering multiple myeloma.
Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM
J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
5. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
[TBL] [Abstract][Full Text] [Related]
6. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
[TBL] [Abstract][Full Text] [Related]
7. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
Ledergor G; Weiner A; Zada M; Wang SY; Cohen YC; Gatt ME; Snir N; Magen H; Koren-Michowitz M; Herzog-Tzarfati K; Keren-Shaul H; Bornstein C; Rotkopf R; Yofe I; David E; Yellapantula V; Kay S; Salai M; Ben Yehuda D; Nagler A; Shvidel L; Orr-Urtreger A; Halpern KB; Itzkovitz S; Landgren O; San-Miguel J; Paiva B; Keats JJ; Papaemmanuil E; Avivi I; Barbash GI; Tanay A; Amit I
Nat Med; 2018 Dec; 24(12):1867-1876. PubMed ID: 30523328
[TBL] [Abstract][Full Text] [Related]
8. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
[TBL] [Abstract][Full Text] [Related]
9. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Visram A; Cook J; Warsame R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
[TBL] [Abstract][Full Text] [Related]
11. Smoldering multiple myeloma - Past, present, and future.
Mann H; Katiyar V; Varga C; Comenzo RL
Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
[TBL] [Abstract][Full Text] [Related]
12. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
[TBL] [Abstract][Full Text] [Related]
13. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
Bustoros M; Anand S; Sklavenitis-Pistofidis R; Redd R; Boyle EM; Zhitomirsky B; Dunford AJ; Tai YT; Chavda SJ; Boehner C; Neuse CJ; Rahmat M; Dutta A; Casneuf T; Verona R; Kastritis E; Trippa L; Stewart C; Walker BA; Davies FE; Dimopoulos MA; Bergsagel PL; Yong K; Morgan GJ; Aguet F; Getz G; Ghobrial IM
Nat Commun; 2022 Jun; 13(1):3449. PubMed ID: 35705541
[TBL] [Abstract][Full Text] [Related]
14. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
15. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C; Manasanch EE
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
[TBL] [Abstract][Full Text] [Related]
16. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
[TBL] [Abstract][Full Text] [Related]
17. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chojnacka M; Diamond B; Landgren O; Maura F
Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
[TBL] [Abstract][Full Text] [Related]
18. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
19. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T; Schoebe N; Mai S
Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
[TBL] [Abstract][Full Text] [Related]
20. Smoldering multiple myeloma: taking the narrow over the wide path?
Avet-Loiseau H; Bahlis NJ
Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
